Literature DB >> 8440759

Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids.

H Derendorf1, G Hochhaus, H Möllmann, J Barth, M Krieg, S Tunn, C Möllmann.   

Abstract

The pharmacodynamics of three corticosteroids were investigated after intravenous administration of the phosphate esters of methylprednisolone, dexamethasone, and triamcinolone acetonide to healthy subjects at 20, 50, and 80 mg as well as placebo. Twenty-two different pharmacodynamic parameters were followed as a function of time for 48 hours. Statistically significant effects of the glucocorticoids were an increase in blood glucose levels, a decrease in the number of lymphocytes, eosinophils, basophils, and monocytes, and an increase in the number of granulocytes and stab cells. For the most significant pharmacodynamic effects (lymphocytes, granulocytes, and glucose) a previously derived integrated pharmacokinetic/pharmacodynamic model using plasma concentrations, protein-binding data, and in vitro receptor-binding affinities was used to predict the pharmacodynamic effect-time profiles. Good agreement of predicted and measured effects was observed, confirming the validity of the model. The clinical significance of the model was demonstrated by comparison of model-predicted maintenance doses with empirically determined clinical equivalency doses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8440759     DOI: 10.1002/j.1552-4604.1993.tb03930.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  16 in total

1.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

2.  Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide.

Authors:  Jeffrey G Stark; Sybille Werner; Susanne Homrighausen; Yufei Tang; Michael Krieg; Hartmut Derendorf; Helmut Moellmann; Guenther Hochhaus
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-22       Impact factor: 2.745

Review 3.  Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling.

Authors:  Elizabeth C M de Lange; Paulien G M Ravenstijn; Dorien Groenendaal; Tamara J van Steeg
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

Review 4.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Altered leucocyte trafficking and suppressed tumour necrosis factor alpha release from peripheral blood monocytes after intra-articular glucocorticoid treatment.

Authors:  J H Steer; D T Ma; L Dusci; G Garas; K E Pedersen; D A Joyce
Journal:  Ann Rheum Dis       Date:  1998-12       Impact factor: 19.103

6.  Postoperative leukocyte changes in facial fracture patients: a randomized prospective study with short-term dexamethasone.

Authors:  Johanna Snäll; Jyrki Törnwall; Anna Liisa Suominen; Hanna Thorén
Journal:  Oral Maxillofac Surg       Date:  2017-04-06

Review 7.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

8.  Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies in rats.

Authors:  G Hochhaus; R J Gonzalez-Rothi; A Lukyanov; H Derendorf; H Schreier; T Dalla Costa
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

Review 9.  In silico prediction of brain exposure: drug free fraction, unbound brain to plasma concentration ratio and equilibrium half-life.

Authors:  Morena Spreafico; Matthew P Jacobson
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

10.  Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate.

Authors:  Zia R Tayab; Tom C Fardon; Daniel K C Lee; Kay Haggart; Lesley C McFarlane; Brian J Lipworth; Günther Hochhaus
Journal:  Br J Clin Pharmacol       Date:  2007-05-17       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.